(Q38260098)

1 September 2017

1 reference

title

Sorting out the risks in progressive multifocal leukoencephalopathy (English)

1 reference

progressive multifocal leukoencephalopathy

1 September 2017

0 references

2

Eamonn Molloy

1 reference

1 September 2017

Leonard H Calabrese

1

1 reference

1 September 2017

Joseph Berger

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

14 October 2014

1 reference

Nature Reviews Rheumatology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

2

1 reference

1 September 2017

119-123

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.167

1 September 2017

0 references

cites work

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

The bone marrow, B cells, and JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Risk factors for rare diseases can be risky to define: PML and natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

PML and rheumatology: the contribution of disease and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Goal-oriented patient care--an alternative health outcomes paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

JC viremia in natalizumab-treated patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

JC virus antibody status underestimates infection rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

The basis for modeling progressive multifocal leukoencephalopathy pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Therapy: Targeted but not trouble-free: efalizumab and PML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Drug-induced PML: a global agenda for a global challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.167

Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25314016

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The pathogenesis of progressive multifocal leukoencephalopathy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25314016

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2014.167

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference